发明名称 Targeted Treatment of Anerobic Cancer
摘要 The present invention relates to a pharmaceutical cocktail and methods of treatment involving said cocktail, in particular, a combination of effective amounts of a carbonic anhydrase inhibitor, in combination with effective amounts of an angiogenesis inhibitor, including a vascular endothelial growth factor (VEGF) inhibitor such as bevacizumab for the treatment of cancer. In other embodiments, it relates to compositions and methods of treating cancer involving effective amounts of a carbonic anhydrase inhibitor. Pharmaceutical compositions and methods of treating cancer (eliminating the tumor, shrinking the tumor, prolonging the life of the patient, increasing quality of life by decreasing the grade of adverse events seen with other cancer treatments, and/or preventing/reducing the likelihood of the tumor's metastases) are additional aspects of the present invention. In addition, the present invention may be used to favorably impact the therapeutic result of patients who have not responded to alternative, traditional anti-cancer therapy.
申请公布号 US2017056350(A1) 申请公布日期 2017.03.02
申请号 US201615229720 申请日期 2016.08.05
申请人 University Hospitals Cleveland Medical Center 发明人 Haaga John R.;Haaga Rebecca
分类号 A61K31/196;A61K31/44;C07K16/22;A61K39/395;A61K47/34;A61K45/06 主分类号 A61K31/196
代理机构 代理人
主权项
地址 Cleveland OH US
您可能感兴趣的专利